Independent Predictors of Steatohepatitis and Fibrosis in Asian Indian Patients with Non-Alcoholic Steatohepatitis

被引:0
|
作者
Deepak Kumar Singh
Puja Sakhuja
Veena Malhotra
Ranjana Gondal
Shiv Kumar Sarin
机构
[1] Govind Ballabh Pant Hospital,Department of Pathology
[2] Govind Ballabh Pant Hospital,Department of Gastroenterology
来源
关键词
Asian-Indian; Liver; NASH; Non-alcoholic steatohepatitis; Predictors;
D O I
暂无
中图分类号
学科分类号
摘要
Aim To identify the clinical and biochemical predictors of histologic disease severity in patients with non-alcoholic steatohepatitis (NASH). Method Clinical, anthropometric and biochemical data of 71 consecutive patients with a histological diagnosis of NASH were retrieved from the medical database. The histologic criteria proposed at the American Association for the Study of Liver Diseases Conference (2003) were followed. Histologic features and the necro-inflammatory grade of liver biopsy were scored in accordance with the Brunt score. Statistical analysis was performed to identify predictors of disease severity. Results The male to female ratio of the study cohort was 3.1:1. The mean body mass index (BMI) of the patients was 25.67 ± 1.9 kg/m2. In terms of necroinflammatory grading, 21 (29.6%) patients were classified as grade 1, 26 (36.6%) as grade 2 and 24 (33.8%) as grade 3. Multivariate analysis revealed that BMI (P = 0.009), waist circumference (P = 0.035), waist:hip ratio (P = 0.011) and aspartate aminotransferase levels (P < 0.001) were independent predictors of necroinflammatory grade and that female gender (P = 0.02), serum alkaline phosphatase levels (P = 0.018), cholesterol levels (P = 0.048) and low-density lipoprotein (LDL) levels (P = 0.025) were independent predictors of fibrosis stage. Conclusion Female gender, BMI, waist:hip ratio, hypercholesterolemia and LDL levels are independent predictors of disease severity in patients with NASH and may influence the decision to biopsy.
引用
收藏
页码:1967 / 1976
页数:9
相关论文
共 50 条
  • [41] Metformin in the treatment of patients with non-alcoholic steatohepatitis
    Uygun, A
    Kadayifci, A
    Isik, AT
    Ozgurtas, T
    Deveci, S
    Tuzun, A
    Yesilova, Z
    Gulsen, M
    Dagalp, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (05) : 537 - 544
  • [42] Liraglutide for patients with non-alcoholic steatohepatitis Reply
    Newsome, Philip N.
    Armstrong, Matthew J.
    Gaunt, Piers
    LANCET, 2016, 387 (10036): : 2379 - 2379
  • [43] Bariatric Surgery for Patients with non-alcoholic Steatohepatitis
    Roeb, Elke
    Nitschmann, Sirka
    INNERE MEDIZIN, 2023, 64 (11): : 1130 - 1132
  • [44] Prevalence of obesity in patients with non-alcoholic steatohepatitis
    Edwards, MS
    Kaushik, VP
    Ankoma-Sey, V
    FASEB JOURNAL, 2000, 14 (04): : A500 - A500
  • [45] Saroglitazar for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 698 - 698
  • [46] Mechanisms of non-alcoholic steatohepatitis
    McClain, CJ
    Mokshagundam, PL
    Barve, SS
    Song, ZY
    Hill, DB
    Chen, T
    Deaciuc, I
    ALCOHOL, 2004, 34 (01) : 67 - 79
  • [47] Drugs and non-alcoholic steatohepatitis
    Farrell, GC
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 132 - 139
  • [48] Obesity and non-alcoholic steatohepatitis
    García-Monzón, C
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 117 - 123
  • [49] Non-alcoholic steatohepatitis in morbidly obese patients
    Ong, JP
    Elariny, H
    Younoszai, A
    Collantes, RS
    Goodman, Z
    Chandhoke, V
    Younossi, ZM
    OBESITY RESEARCH, 2004, 12 : A49 - A49
  • [50] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    LANCET, 2001, 358 (9285): : 893 - 894